Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) Wakelee, H., Yu, W., Rittweger, K., Paton, V. E. OXFORD UNIV PRESS. 2012: 445
View details for Web of Science ID 000309409002297